A coronavirus vaccine developed by China’s Sinovac Biotech was found to be just 50.4 percent effective at preventing symptomatic infections of COVID-19 in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last
The Chinese firm has already reached deals to supply the CoronaVac inoculation to countries including Indonesia and Turkey. China’s Sinovac Biotech has secured $515m in funding to double the production capacity of its coronavirus vaccine, it said on Monday, with efficacy data